EDEN RESEARCH PLC

Management Reports • Feb 2, 2015

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 6854D

Eden Research plc

02 February 2015

Eden Research Plc

("Eden" or "Company")

Grant of Patent in South Korea

Eden Research plc (AIM: EDEN), the AIM-listed biopesticide and encapsulation company, announces that it has been granted a Patent from the Korean Intellectual Property Office covering the composition and use of its key active terpene-based ingredients (Patent No. 10-1478012).

The patent specifically covers, "Compositions and Methods Comprising Terpenes or Terpene Mixtures selected from Thymol, Eugenol, Geraniol, Citral, and L-Carvone." This grant widens the patent coverage in South Korea from the patent announced in July 2014 which encompassed the application of Eden's encapsulation and terpene technology for killing mites.

Sean Smith Managing Director of Eden comments: "Our intellectual property is a key value driver for the business and its licensees and so the continued widening of our patent protection across multiple geographies is an important goal for the team. As we've mentioned before, the crop protection market in South Korea is substantial and this additional patent offers us excellent protection as we continue to move closer to the commercial launch of products using our technologies worldwide."

Eden Research plc	www.edenresearch.com
Sean Smith, Chief Executive Officer	Tel: 01993 862 761
Alex Abrey, Chief Financial Officer
W H Ireland Limited	Tel: 0117 945 3471
John Wakefield
Walbrook PR Ltd	Tel: 020 7933 8780 or eden@walbrookpr.com
Paul McManus	Mob: 07980 541 893
Lianne Cawthorne	Mob: 07584 391 303

Notes:

Eden is an early stage revenue company with intellectual property and expertise in encapsulation, terpenes and environmentally friendly technologies to provide naturally occurring solutions to the global agrochemicals industry, the animal health industry, and consumer products.

Eden's encapsulation technology harnesses the biocidal efficacy of naturally occurring chemicals produced by plants (terpenes) and can also be used with hydrophobic compounds both natural and synthetic. The technology uses yeast cells to deliver a slow release of natural compounds for agricultural and non-agricultural uses. Terpenes are already widely used in the food flavouring, cosmetic and pharmaceutical industries.

Historically, terpenes have had limited commercial use in the agrochemical sector due to their volatility, phytotoxicity and poor solubility. Eden's platform encapsulation technology provides a unique, environmentally friendly solution to these problems and enables terpenes to be used as effective, low-risk agrochemicals.

With leading consultants in their respective fields, the Company is developing these technologies through innovative research and a series of commercial production, marketing and distribution partnerships.

The Company has a number of patents and has a pipeline of products at differing stages of development targeting specific areas of the global agrochemicals industry. To date, the Company has invested in the region of £12m in developing and protecting its intellectual property. Revenues earned by the Company have been modest whilst the Company has concentrated on securing patent protection for its intellectual property, identifying suitable industrial partners and entering into licence agreements.

Eden was admitted to trading on AIM on 11 May 2012 and trades under the symbol EDEN.

For more information about Eden, please visit www.edenresearch.com 

This information is provided by RNS

The company news service from the London Stock Exchange

END

MSCZMGFMNGRGKZM